Legislation – The Health Protection (Coronavirus, Restrictions) (Self-Isolation) (England) (Amendment) Regulations 2021
Changes to legislation:
There are currently no known outstanding effects for The Health Protection (Coronavirus, Restrictions) (Self-Isolation) (England) (Amendment) Regulations 2021, Section 2.
Changes to Legislation
Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.
Amendments to the Health Protection (Coronavirus, Restrictions) (Self-Isolation) (England) Regulations 20202.
(1)
The Health Protection (Coronavirus, Restrictions) (Self-Isolation) (England) Regulations 2020 are amended as follows.
(2)
In regulation 2(2)—
(a)
in sub-paragraph (l), after “coronavirus” insert “
;
or antibodies to coronavirus
”
(b)
in sub-paragraph (m), omit the words from “, or give agreement” to “child to participate,”.
(3)
In regulation 2B—
(a)
in paragraph (1)—
(i)
at the end of sub-paragraph (a), omit “or”;
(ii)
omit sub-paragraph (b);
(b)
in paragraph (2), in the opening words, after “unless” insert “
;
paragraph (6) applies or
”
(c)
omit paragraph (3);
(d)
in paragraphs (4) and (5), omit “, or R where P is a child,”;
(e)
“(6)
This paragraph applies if—
(a)
the person (“NP”) has completed a course of doses of an authorised vaccine, and
(i)
that course of doses was administered to NP in the United Kingdom, and
(ii)
the day on which NP had the close contact which resulted in the notification described in paragraph (1) is more than 14 days after the day on which NP completed that course of doses,
(b)
NP has participated, or is participating, in a clinical trial of a vaccine for vaccination against coronavirus carried out in the United Kingdom in accordance with the requirements of the Medicines for Human Use (Clinical Trials) Regulations 2004 M1, or
(c)
NP is able to provide evidence that, for clinical reasons, NP should not be vaccinated with any authorised vaccine.
(7)
For the purposes of paragraph (6), a person has completed a course of doses if that person has received the complete course of doses specified—
(a)
in the summary of product characteristics approved as part of the marketing authorisation for the authorised vaccine, or
(b)
in the instructions for usage approved as part of the authorisation by the licensing authority on a temporary basis under regulation 174 (supply in response to spread of pathogenic agents etc) of the Human Medicines Regulations 2012 M2 for the authorised vaccine.
(8)
In this regulation—
“authorised vaccine” means a medicinal product—
(a)
authorised for supply in the United Kingdom in accordance with a marketing authorisation, or
(b)
authorised by the licensing authority on a temporary basis under regulation 174 of the Human Medicines Regulations 2012,
for vaccination against coronavirus;
“clinical trial” has the meaning given in regulation 2(1) (interpretation) of the Medicines for Human Use (Clinical Trials) Regulations 2004;
“the licensing authority” has the meaning given in regulation 6(2) (the licensing authority and the Ministers) of the Human Medicines Regulations 2012;
“marketing authorisation” has the meaning given in regulation 8(1) (general interpretation) of the Human Medicines Regulations 2012;
“medicinal product” has the meaning given in regulation 2 (medicinal products) of the Human Medicines Regulations 2012.”.
(4)
In regulation 2D—
(a)
in paragraph (1)—
(i)
in sub-paragraph (a), omit “or (b)”;
(ii)
in sub-paragraph (e), omit “, or R, where P is a child, agrees to P participating”;
(b)
in paragraph (2), in the opening words, omit “or (3)(a) (as the case may be)”;
(c)
in paragraph (3)(b), omit “, or R, where P is a child, receives a further notification in respect of P,”;
(d)
in paragraph (4), omit “, or R where P is a child,”;
(e)
in paragraph (5)—
(i)
in sub-paragraph (b), omit “, or R where P is a child,”;
(ii)
in the closing words, omit “or R (as the case may be)”;
(f)
in paragraph (6)—
(i)
in the definition of “the relevant period of self-isolation”, omit “or R (as the case may be)”;
(ii)
in the definition of “the relevant notification”, omit “or (b)”.
(5)
In regulation 3(4), in the opening words, omit “or (b)”.
(6)
In regulation 5(1), in the definition of “P”, for “2B(2) or 2B(3)”, substitute “
.
or 2B(2)
”
(7)
In regulation 10(4), omit “or 2B”.
(8)
In regulation 14(4D)(a)(ii), omit “or (b)”.
(9)
“Transitional provision19.
Where—
(a)
a person (“Y”)—
(i)
satisfies the conditions in regulation 2B(6)(a), (b) or (c), or is a child, and
(ii)
is subject to the self-isolation requirement in regulation 2B(2) or (3) immediately before 16th August 2021, and
(b)
Y’s period of self-isolation would, apart from this regulation, continue beyond that date,
the period of self-isolation for Y comes to an end at the beginning of 16th August 2021.”.